IDEAS home Printed from https://ideas.repec.org/a/spr/hecrev/v3y2013i1p1-1110.1186-2191-1991-3-27.html
   My bibliography  Save this article

Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?

Author

Listed:
  • Stefanie Knoll
  • Christoph Mair
  • Ursula Benter
  • Katja Vouk
  • Baudouin Standaert

Abstract

Routine rotavirus vaccination in Germany would reduce the number of hospitalised and outpatient cases. The associated investment could be fully offset by costs avoided in hospital stays, physician visits and SHI reimbursement of productivity losses. Sensitivity analysis indicated that vaccination would be cost-saving in 95% of simulations. Incremental cost was observed only under extreme conditions, especially when the time spent at home due to rotavirus disease was low or when vaccine efficacy against severe disease was heavily decreased. Copyright Knoll et al.; licensee Springer. 2013

Suggested Citation

  • Stefanie Knoll & Christoph Mair & Ursula Benter & Katja Vouk & Baudouin Standaert, 2013. "Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?," Health Economics Review, Springer, vol. 3(1), pages 1-11, December.
    • Handle: RePEc:spr:hecrev:v:3:y:2013:i:1:p:1-11:10.1186/2191-1991-3-27
    DOI: 10.1186/2191-1991-3-27
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1186/2191-1991-3-27
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1186/2191-1991-3-27?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. H. Melliez & D. Levy-Bruhl & P. Y. Boelle & B. Dervaux & S. Baron & Y. Yazdanpanah, 2008. "Cost and cost-effectiveness of childhood vaccination against rotavirus in France," Post-Print hal-00283456, HAL.
    2. Joke Bilcke & Philippe Beutels, 2009. "Reviewing the Cost Effectiveness of Rotavirus Vaccination," PharmacoEconomics, Springer, vol. 27(4), pages 281-297, April.
    3. Joke Bilcke & Pierre Van Damme & Philippe Beutels, 2009. "Cost-Effectiveness of Rotavirus Vaccination: Exploring Caregiver(s) and ``No Medical Care'' Disease Impact in Belgium," Medical Decision Making, , vol. 29(1), pages 33-50, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Joke Bilcke & Pierre Van Damme & Marc Van Ranst & Niel Hens & Marc Aerts & Philippe Beutels, 2009. "Estimating the Incidence of Symptomatic Rotavirus Infections: A Systematic Review and Meta-Analysis," PLOS ONE, Public Library of Science, vol. 4(6), pages 1-10, June.
    2. Marisa Holubar & Maria Christina Stavroulakis & Yvonne Maldonado & John P A Ioannidis & Despina Contopoulos-Ioannidis, 2017. "Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis," PLOS ONE, Public Library of Science, vol. 12(3), pages 1-22, March.
    3. Hareth Al-Janabi & Terry Flynn & Joanna Coast, 2011. "QALYs and Carers," PharmacoEconomics, Springer, vol. 29(12), pages 1015-1023, December.
    4. Hareth Al‐Janabi & Job Van Exel & Werner Brouwer & Caroline Trotter & Linda Glennie & Laurie Hannigan & Joanna Coast, 2016. "Measuring Health Spillovers for Economic Evaluation: A Case Study in Meningitis," Health Economics, John Wiley & Sons, Ltd., vol. 25(12), pages 1529-1544, December.
    5. Hareth Al-Janabi & Andrea Manca & Joanna Coast, 2017. "Predicting carer health effects for use in economic evaluation," PLOS ONE, Public Library of Science, vol. 12(9), pages 1-18, September.
    6. Joke Bilcke & Philippe Beutels, 2009. "Reviewing the Cost Effectiveness of Rotavirus Vaccination," PharmacoEconomics, Springer, vol. 27(4), pages 281-297, April.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:hecrev:v:3:y:2013:i:1:p:1-11:10.1186/2191-1991-3-27. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/13561 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.